Seastar Medical Holding Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated May 15, 2023, reports the financial condition and results of operations for Seastar Medical Holding Corp. for the fiscal quarter ended March 31, 2023. The company is an emerging growth company incorporated in Delaware, with its principal executive offices in Denver, CO. Its common stock (ICU) and warrants (ICUCW) trade on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release furnished as Exhibit 99.1, which is referenced but not included in the provided text.
Material Changes
The filing does not detail specific material changes versus the prior comparable period. It serves as a notification that the Q1 2023 results have been announced via a press release.
Guidance, Outlook, and Risks
The filing does not contain specific guidance, outlook, management commentary, or risk factors within the text provided. It explicitly states that the information in the press release (Exhibit 99.1) is "furnished" and not "filed" for purposes of Section 18 of the Exchange Act, meaning it is not subject to the liabilities of that section and shall not be deemed incorporated by reference into other filings.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 15, 2023) for actual Q1 2023 financial figures.
- Verify the company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.
- Confirm the trading status of Common Stock (ICU) and Warrants (ICUCW) on Nasdaq.
- Note that the financial data in the press release is not incorporated by reference into this 8-K filing.